A Single-centre, Single-dose, Open-label and Self-control Study to Evaluate the Effect of Efavirenz on Pharmacokinetic of SHR6390 in Healthy Chinese Subjects
Latest Information Update: 04 Dec 2021
At a glance
- Drugs Dalpiciclib (Primary) ; Efavirenz (Primary)
- Indications Breast cancer; Head and neck cancer; Malignant melanoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
- 25 Nov 2021 Status changed from not yet recruiting to completed.
- 27 Jul 2021 New trial record